Glasgow, United Kingdom

Angelo Pugliese

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Angelo Pugliese: Innovator in Cancer Treatment

Introduction

Angelo Pugliese is a notable inventor based in Glasgow, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the creation of new therapeutic agents aimed at combating proliferative diseases, particularly cancer.

Latest Patents

Angelo Pugliese holds a patent for Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer. The patent describes a compound of Formula I, or a salt, hydrate, or solvate thereof, which has been found to exhibit pharmacological effects, especially at MRCK. The invention also includes pharmaceutical compositions comprising these compounds, highlighting their potential as therapeutic agents for the treatment and prevention of cancer.

Career Highlights

Pugliese is associated with Cancer Research Technology Limited, where he has been instrumental in advancing cancer research. His dedication to developing effective treatments showcases his commitment to improving patient outcomes in the fight against cancer.

Collaborations

Angelo has collaborated with esteemed colleagues such as Stuart Francis and Duncan McArthur. Their combined expertise has contributed to the success of their research initiatives and the development of innovative cancer therapies.

Conclusion

Angelo Pugliese's work exemplifies the vital role of inventors in the medical field, particularly in the ongoing battle against cancer. His innovative compounds and dedication to research are paving the way for new treatment options that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…